Hepion Pharmaceuticals, Inc. (HEPA) shareholders
Close on Oct 19, 2026Market cap $7.26MP/E –Yield –
Ownership
Who owns Hepion Pharmaceuticals's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vincent LoPriore Joint filing with Gravitas Capital LP (21.40%), Invictus Capital Advisors Pension Plan (5.70%) | 26,250,000 | 26.20% | 13D (active) amendment | Aug 3, 2026 |
| Gravitas Collective Corp. | 25,000,000 | 19.90% | 13D (active) | Oct 6, 2026 |
| Black Global 5 LLC Joint filing with Red Global 3, LLC (11.10%), Darin Feinstein (11.10%) | 10,000,000 | 11.10% | 13D (active) | Jul 31, 2026 |
| KI Holdings Ltd. | 10,000,000 | 10.20% | 13D (active) amendment | Aug 3, 2026 |
| Kenneth Rickel | 7,250,000 | 7.20% | 13G (passive) amendment | Oct 20, 2026 |
| Gary Stetz | 5,250,000 | 5.70% | 13D (active) | Aug 3, 2026 |
| Sireesh Appajosyula | 5,250,000 | 5.70% | 13D (active) | Aug 3, 2026 |
| Bigger Capital Fund GP, LLC Joint filing with Bigger Capital Fund L P (9.99%), Bigger Michael (9.99%) | 1,060,883 | 9.99% | 13G (passive) | Jan 21, 2025 |
| Anson Funds Management LP Joint filing with Anson Management GP LLC (9.90%), Tony Moore (9.90%) and 3 more | 595,719 | 9.90% | 13G (passive) | Mar 31, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Sireesh Appajosyula | Chief Executive Officer, Director | 3,250,000 | Oct 27, 2026 |
| Vincent S. LoPriore | Executive Chairman, Director | 30,500,000 | Oct 27, 2026 |
| Gary S. Stetz | Chief Financial Officer, Director | 4,500,000 | Oct 27, 2026 |
| Chase LoPriore | VP, Corp. Dev., Director | 1,250,000 | Oct 27, 2026 |
| James Gordon Liddy | Director | – | Oct 27, 2026 |
| Danina Fisher | Director | 200,000 | Oct 27, 2026 |
| Gary S. Stetz II | Director | 500,000 | Oct 27, 2026 |
| Michael J. Purcell | Director | 3,250,000 | Oct 27, 2026 |
| Collective Corp. Gravitas | Director | 25,000,000 | Oct 21, 2026 |
| KI Holdings, Ltd. | 10% owner | 10,000,000 | Sep 16, 2026 |
| Global 5 LLC Black | 10% owner | 10,000,000 | Aug 7, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Danina Fisher Director | Sep 29, 2026 | Buy | +200,000 | $0.05 | $10.00K | 200,000 |
| Michael J. Purcell Director | Aug 3, 2026 | Buy | +2,000,000 | $0.05 | $100.00K | 3,250,000 |
| Gary S. Stetz Interim CEO, Director | Aug 3, 2026 | Buy | +2,000,000 | $0.05 | $100.00K | 3,250,000 |
| Sireesh Appajosyula Chief Operating Officer, Director | Aug 3, 2026 | Buy | +2,000,000 | $0.05 | $100.00K | 3,250,000 |
| Vincent S. LoPriore Executive Chairman, Director | Aug 3, 2026 | Buy | +8,000,000 | $0.05 | $400.00K | 14,250,000 |
| Vincent S. LoPriore Executive Chairman, Director | Aug 3, 2026 | Buy | +2,000,000 | $0.05 | $100.00K | 16,250,000 |
| Gary S. Stetz II Director | Aug 3, 2026 | Buy | +500,000 | $0.05 | $25.00K | 500,000 |
| Michael J. Purcell Director | Apr 21, 2026 | Buy | +1,250,000 | $0.04 | $50.00K | 1,250,000 |
| Gary S. Stetz Interim CEO, Director | Apr 21, 2026 | Buy | +1,250,000 | $0.04 | $50.00K | 1,250,000 |
| Sireesh Appajosyula Director | Apr 21, 2026 | Buy | +1,250,000 | $0.04 | $50.00K | 1,250,000 |
| Vincent S. LoPriore Executive Chairman, Director, 10% owner | Apr 21, 2026 | Buy | +5,000,000 | $0.04 | $200.00K | 5,000,000 |
| Vincent S. LoPriore Executive Chairman, Director, 10% owner | Apr 21, 2026 | Buy | +1,250,000 | $0.04 | $50.00K | 6,250,000 |
| Peter Wijngaard Director | Nov 27, 2023 | Buy | +2,500 | $3.05 | $7.63K | 9,501 |
| Peter Wijngaard Director | Nov 24, 2023 | Buy | +2,500 | $3.09 | $7.73K | 7,001 |
| Peter Wijngaard Director | Sep 19, 2023 | Buy | +1,000 | $5.64 | $5.64K | 4,501 |
| Robert T. Foster CEO and Director | Sep 18, 2023 | Buy | +1,600 | $5.60 | $8.96K | 50,470 |
| Peter Wijngaard Director | Sep 15, 2023 | Buy | +1,000 | $5.82 | $5.82K | 2,501 |
| Peter Wijngaard Director | Sep 15, 2023 | Buy | +139 | $5.45 | $758 | 2,640 |
| Peter Wijngaard Director | Sep 15, 2023 | Buy | +861 | $5.37 | $4.62K | 3,501 |
| Robert T. Foster CEO,CSO and Director | Sep 15, 2023 | Buy | +1,600 | $5.40 | $8.64K | 48,870 |
| John T. Cavan Chief Financial Officer | Feb 18, 2021 | Buy | +10,000 | $2.00 | $20.00K | 14,800 |
| Robert T. Foster CEO and Director | Feb 18, 2021 | Buy | +20,000 | $2.00 | $40.00K | 45,259 |
| Peter Wijngaard Director | Feb 16, 2021 | Buy | +10,000 | $2.20 | $22.00K | 30,000 |
| Peter Wijngaard Director | Dec 18, 2020 | Buy | +20,000 | $1.91 | $38.20K | 20,000 |
| Robert T. Foster CEO and Director | Dec 8, 2020 | Buy | +25,000 | $1.58 | $39.50K | 25,259 |
| John P. Brancaccio Director | Dec 2, 2020 | Buy | +7,000 | $1.53 | $10.71K | 7,008 |
| Gary S. Jacob Director | Dec 1, 2020 | Buy | +12,000 | $1.66 | $19.92K | 12,059 |
| John T. Cavan Chief Financial Officer | Nov 25, 2020 | Buy | +4,500 | $1.62 | $7.29K | 4,800 |
| John T. Cavan CFO | Jan 3, 2018 | Award | +101,221 | – | – | 167,947 |
| Robert T. Foster Chief Scientific Officer | Jan 3, 2018 | Award | +100,654 | – | – | 144,736 |
| James Sapirstein Chief Executive Officer, Director | Jan 3, 2018 | Award | +322,092 | – | – | 492,819 |
| Robert T. Foster Chief Scientific Officer | Jul 6, 2017 | Award | +44,082 | – | – | 44,082 |
| John Z. Sullivan-Bolyai Chief Medical Officer | Jul 6, 2017 | Award | +58,681 | – | – | 58,681 |
| James Sapirstein Chief Executive Officer, Director | Jul 6, 2017 | Award | +141,061 | – | – | 170,727 |
| John T. Cavan CFO | Jul 6, 2017 | Award | +46,726 | – | – | 66,726 |
| John T. Cavan CFO | Jun 20, 2017 | Buy | +20,000 | $0.65 | $13.00K | 20,000 |
| James Sapirstein Chief Executive Officer, Director | Oct 27, 2016 | Option exercise | +16,666 | $1.50 | $25.00K | 29,666 |
| James Sapirstein Chief Executive Officer, Director | Feb 18, 2016 | Buy | +10,000 | $1.00 | $10.00K | 13,000 |
| James Sapirstein Chief Executive Officer, Director | Nov 30, 2015 | Buy | +500 | $2.15 | $1.08K | 3,000 |
| James Sapirstein Chief Executive Officer, Director | Nov 23, 2015 | Buy | +2,500 | $1.64 | $4.10K | 2,500 |
| John P. Brancaccio Director | Mar 4, 2014 | Buy | +4,393 | $1.49 | $6.55K | 6,408 |
| Bernard Denoyer Chief Financial Officer | Feb 18, 2014 | Other | +1,030 | – | – | 1,030 |
| Synergy Pharmaceuticals, Inc. 10% owner | Feb 18, 2014 | Other | −9,000,000 | – | – | 0 |
| Gary S. Jacob CEO and President, Director | Feb 18, 2014 | Other | +32,935 | – | – | 32,935 |
| John P. Brancaccio Director | Feb 18, 2014 | Other | +2,015 | – | – | 2,015 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Hepion Pharmaceuticals's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
See a number that looks wrong?